172 related articles for article (PubMed ID: 35050996)
1. Use of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) (BAT
Parrera GS; Astacio H; Tunga P; Anderson DM; Hall CL; Richardson JS
Toxins (Basel); 2021 Dec; 14(1):. PubMed ID: 35050996
[TBL] [Abstract][Full Text] [Related]
2. Safety and Clinical Outcomes of an Equine-derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States.
Richardson JS; Parrera GS; Astacio H; Sahota H; Anderson DM; Hall C; Babinchak T
Clin Infect Dis; 2020 Apr; 70(9):1950-1957. PubMed ID: 31209461
[TBL] [Abstract][Full Text] [Related]
3. Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent product.
Anderson DM; Kumar VR; Arper DL; Kruger E; Bilir SP; Richardson JS
PLoS One; 2019; 14(11):e0224700. PubMed ID: 31697731
[TBL] [Abstract][Full Text] [Related]
4. Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin.
Yu PA; Lin NH; Mahon BE; Sobel J; Yu Y; Mody RK; Gu W; Clements J; Kim HJ; Rao AK
Clin Infect Dis; 2017 Dec; 66(suppl_1):S57-S64. PubMed ID: 29293928
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs.
Barker D; Gillum KT; Niemuth NA; Kodihalli S
PLoS One; 2019; 14(9):e0222670. PubMed ID: 31527885
[TBL] [Abstract][Full Text] [Related]
6. Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review.
Schussler E; Sobel J; Hsu J; Yu P; Meaney-Delman D; Grammer LC; Nowak-Wegrzyn A
Clin Infect Dis; 2017 Dec; 66(suppl_1):S65-S72. PubMed ID: 29293931
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques.
Kodihalli S; Emanuel A; Takla T; Hua Y; Hobbs C; LeClaire R; O'Donnell DC
PLoS One; 2017; 12(11):e0186892. PubMed ID: 29166654
[TBL] [Abstract][Full Text] [Related]
8. Exposure-Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product.
Beliveau M; Anderson D; Barker D; Kodihalli S; Simard E; Hall C; Richardson JS
Clin Pharmacol Ther; 2022 Jul; 112(1):171-180. PubMed ID: 35467014
[TBL] [Abstract][Full Text] [Related]
9. Foodborne botulism treated with heptavalent botulism antitoxin.
Hill SE; Iqbal R; Cadiz CL; Le J
Ann Pharmacother; 2013 Feb; 47(2):e12. PubMed ID: 23362041
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of equine botulism antitoxin in botulism poisoning in a guinea pig model.
Emanuel A; Qiu H; Barker D; Takla T; Gillum K; Neimuth N; Kodihalli S
PLoS One; 2019; 14(1):e0209019. PubMed ID: 30633746
[TBL] [Abstract][Full Text] [Related]
11. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(10):299. PubMed ID: 20300057
[TBL] [Abstract][Full Text] [Related]
12. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E.
Hatheway CH; Snyder JD; Seals JE; Edell TA; Lewis GE
J Infect Dis; 1984 Sep; 150(3):407-12. PubMed ID: 6481185
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Botulism and Use of Equine Botulinum Antitoxin in Children: A Systematic Review.
Griese SE; Kisselburgh HM; Bartenfeld MT; Thomas E; Rao AK; Sobel J; Dziuban EJ
Clin Infect Dis; 2017 Dec; 66(suppl_1):S17-S29. PubMed ID: 29293924
[TBL] [Abstract][Full Text] [Related]
14. Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin.
Fagan RP; Neil KP; Sasich R; Luquez C; Asaad H; Maslanka S; Khalil W
Clin Infect Dis; 2011 Nov; 53(9):e125-8. PubMed ID: 21896700
[TBL] [Abstract][Full Text] [Related]
15. Outbreak of foodborne botulism in Alexandria, Egypt: modulating indications for administration of heptavalent botulinum antitoxin.
Ghitani SA; Ghanem MA; Sultan EA; Atef M; Henaidy MF
Environ Sci Pollut Res Int; 2021 Nov; 28(43):61547-61553. PubMed ID: 34184216
[TBL] [Abstract][Full Text] [Related]
16. [Antitoxin accident during botulism].
Chaussinand JP; Loyer JJ; Paulin P
Ann Fr Anesth Reanim; 1992; 11(2):241-2. PubMed ID: 1503305
[No Abstract] [Full Text] [Related]
17. Type E botulism.
Horowitz BZ
Clin Toxicol (Phila); 2010 Nov; 48(9):880-95. PubMed ID: 21171846
[TBL] [Abstract][Full Text] [Related]
18. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism.
Tacket CO; Shandera WX; Mann JM; Hargrett NT; Blake PA
Am J Med; 1984 May; 76(5):794-8. PubMed ID: 6720725
[TBL] [Abstract][Full Text] [Related]
19. Equine botulinum antitoxin for the treatment of infant botulism.
Vanella de Cuetos EE; Fernandez RA; Bianco MI; Sartori OJ; Piovano ML; Lúquez C; de Jong LI
Clin Vaccine Immunol; 2011 Nov; 18(11):1845-9. PubMed ID: 21918119
[TBL] [Abstract][Full Text] [Related]
20. Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt.
Hibbs RG; Weber JT; Corwin A; Allos BM; Abd el Rehim MS; Sharkawy SE; Sarn JE; McKee KT
Clin Infect Dis; 1996 Aug; 23(2):337-40. PubMed ID: 8842274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
